Clinical Trial Update: Angeliq Regulatory Post Marketing Surveillance

View source ↗

Summary

Bayer's Angeliq post-marketing surveillance update summarizes ongoing regulatory safety monitoring in postmenopausal women, including osteoporosis-related indic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause-related Vasomotor Symptoms
• Postmenopausal Osteoporosis

Drugs mentioned

• ANGELIQ (DROSPIRENONE AND ESTRADIOL)

Snippet

Sponsor: Bayer | Conditions: Postmenopausal Period, Osteoporosis, Postmenopausal | Status: COMPLETED